Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SORL1 antisense RNA 1 (SORL1-AS1)
- Target
- SORL1-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Other
01
Overview
SORL1 antisense RNA 1 (SORL1-AS1), also known as 51A, is a long non-coding RNA transcribed in the antisense direction from the first intron of the SORL1 (Sortilin-related receptor 1) gene[2][3][4]. SORL1-AS1 regulates SORL1 expression and splicing, increasing levels of a non-canonical SORL1 isoform associated with reduced trafficking and altered processing of amyloid precursor protein (APP), thereby promoting amyloid-β (Aβ) accumulation. Increased expression of SORL1-AS1 is implicated in the pathogenesis of Alzheimer’s disease, making it a candidate therapeutic target and a potential biomarker for disease risk or progression[1][2][3][4]. There are currently no drugs targeting SORL1-AS1 directly, but strategies aimed at lncRNA modulation are being explored for neurodegenerative disease therapy.
- Other names
- 51AlncRNA 51ASORL1-AS1
02
Mechanism of action
Modulation of SORL1 splicing (promotes pathogenic isoforms), Alters APP trafficking and processing, increasing amyloid-β (Aβ) formation
03
Biological functions
Regulation of alternative splicingRegulation of gene expressionInfluences amyloid precursor protein (APP) processingOther
04
Disease associations
Neurodegenerative diseaseAlzheimer’s diseaseOther
05
Safety considerations
Therapeutic targeting could alter neuronal splicing patterns affecting other genes; off-target effects are a potential concern.
06
Biomarkers
Potential marker for Alzheimer's disease risk and progression
Beyond the preview
Go deeper on SORL1 antisense RNA 1 (SORL1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SORL1 antisense RNA 1 (SORL1-AS1).